HIGH-RISK PATIENTS – Patients on targeted AML therapy
Common Agents
-
- IDH inhibitors: Ivosidenib, Enasidenib (14-19%)
-
- Menin inhibitors: Revumenib, Ziftomenib (25%)
-
- FLT3 inhibitors: Gilteritinib, Quizartinib (less common: 3-5%)
- FLT3 inhibitors: Gilteritinib, Quizartinib (less common: 3-5%)
Diagnosis: 2 or more symptoms required
➢ 7 KEY DIAGNOSTIC CRITERIA & FREQUENCY OF SYMPTOMS
| 1. Dyspnea/Hypoxia | Shortness of breath, low O2 saturation (25.8%) |
| 2. Pulmonary Infiltrates/Effusions | Imaging or clinical findings (22.6%) |
| 3. Edema/Weight Gain | Peripheral edema, rapid weight gain (22.6%) |
| 4. Fever | Unexplained temperature elevation (19.4%) |
| 5. Acute Renal Failure | Rising creatinine (6.5%) |
| 6. Unexplained Leukocytosis | WBC >10,000 cell/L (common) |
| 7. Rash/Lymphadenopathy | More common with IDH inhibitors (3.2%) |
| Severity | Grading |
| Severe | 2 signs/symptoms present |
| Moderate | 3-4 signs/symptoms present |
| Severe | 5 signs/symptoms present |
Next steps upon confirmation of suspected DS
-
- Notify oncology team immediately-patients needevaluation TODAY!
-
- Consider preparing for admission-Many patients require hospitalization.
-
- Anticipate dexamethasone order: IV or PO for a minimum of 3 days.
-
- Do not stop targeted therapy without oncology consultation. Recommendationsfor holding vary on
agent
- Do not stop targeted therapy without oncology consultation. Recommendationsfor holding vary on
Next steps upon confirmation of suspected DS
-
- When in doubt, escalate to the oncology team!
-
- Dyspnea is a common presenting symptom in AML, often attributable to anemia. A thorough medication review is essential to distinguish anemia-related symptoms from those associated with differentiation syndrome.
-
- A single sign or symptom is insufficient for diagnosis; assessment should focus on patterns of presentation.
-
- Prompt dexamethasone initiation is key to successful DS management.